DGAP-Adhoc: Dermapharm Holding SE:
|
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Investment
Dermapharm Holding SE:
06-Jun-2019 / 17:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of insider information pursuant to Section17 (1) 1 of the EU Regulation
no. 596/2014 on market abuse as amended (Market Abuse Regulation -MAR)
Dermapharm Holding SE acquires a stake in fitvia
Grünwald, June 06, 2019 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) via Dermapharm AG concluded an agreement today to acquire a majority stake in fitvia GmbH, a company headquartered in Wiesbaden, Germany. With closing of the transaction, Dermapharm AG is acquiring 70.00 percent of the shares in the company specialized in healthy nutrition. The parties have agreed not to disclose the purchase price.
The purchase agreement is still subject to the approval of the antitrust authority. The Management Board expects the transaction to be completed in the third quarter of 2019.
>End of ad hoc announcement<
Contacts
Investor Relations
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
e-mail: [email protected] |
cometis AG
Claudius Krause
Tel.: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
e-mail: [email protected] |
06-Jun-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
Dermapharm Holding SE |
|
Lil-Dagover-Ring 7 |
|
82031 Grünwald |
|
Germany |
| Phone: |
+49 (0)89 64 86-0 |
| E-mail: |
[email protected] |
| Internet: |
ir.dermapharm.de |
| ISIN: |
DE000A2GS5D8 |
| WKN: |
A2GS5D |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: |
820967 |
| |
| End of Announcement |
DGAP News Service |
820967 06-Jun-2019 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
467,12 |
572,42 |
700,88 |
793,83 |
942,91 |
1.024,78 |
1.135,35 |
| EBITDA1,2 |
108,60 |
139,63 |
168,53 |
184,52 |
354,07 |
344,87 |
287,48 |
| EBITDA-Marge3 |
23,25 |
24,39 |
24,05 |
23,24 |
37,55 |
33,65 |
|
| EBIT1,4 |
92,12 |
107,51 |
119,51 |
136,85 |
298,47 |
243,69 |
182,89 |
| EBIT-Marge5 |
19,72 |
18,78 |
17,05 |
17,24 |
31,65 |
23,78 |
16,11 |
| Jahresüberschuss1 |
77,74 |
75,23 |
77,81 |
85,93 |
208,90 |
132,62 |
60,53 |
| Netto-Marge6 |
16,64 |
13,14 |
11,10 |
10,82 |
22,16 |
12,94 |
5,33 |
| Cashflow1,7 |
86,74 |
159,13 |
100,61 |
131,10 |
250,37 |
288,53 |
219,42 |
| Ergebnis je Aktie8 |
1,56 |
1,41 |
1,43 |
1,59 |
3,89 |
2,49 |
1,16 |
| Dividende8 |
0,00 |
0,77 |
0,80 |
0,88 |
2,17 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Dermapharm Holding |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| A2GS5D |
31,050 |
Halten |
1.671,73 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 13,50 |
24,31 |
0,56 |
17,26 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 3,40 |
7,62 |
1,47 |
9,08 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 1,05 |
0,88 |
2,83 |
05.06.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 15.05.2024 |
27.08.2024 |
14.11.2024 |
28.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -13,03% |
-21,45% |
-26,67% |
-31,40% |
|
|
Dermapharm Holding SE DE000A2GS5D8